SA
AXSM icon

SpiderRock Advisors’s Axsome Therapeutics AXSM Stock Holding History

SpiderRock Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.25M Sell
25,000
-5,000
-17% -$436K 0.04% 301
2024
Q2 		$2.42M Hold
30,000
– – 0.05% 249
2024
Q1 		$2.18M Buy
+30,000
New +$2.52M 0.05% 246
2023
Q4 		– Hold
0
– – – 41

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SpiderRock Advisors's AXSM Position: Q3 2024 in Review

SpiderRock Advisors reduced its Axsome Therapeutics (AXSM) stake by 7.1% in Q3 2024, selling an estimated $436K and leaving 65,008 shares worth $5.84M. The position accounts for 0.09% of the portfolio, ranked #157.

SpiderRock Advisors first reported a position in AXSM in Q1 2024 and has held it in 3 quarters since. 279 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • SpiderRock Advisors held 65,008 shares of Axsome Therapeutics worth $5.84M as of Q3 2024.
  • SpiderRock Advisors sold 5,000 Axsome Therapeutics shares in Q3 2024, an estimated $436K.
  • Axsome Therapeutics made up 0.09% of SpiderRock Advisors's portfolio in Q3 2024, its #157 holding.
  • SpiderRock Advisors first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 279 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.